+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Chemotherapy Induced Anemia Market by Range Of Anemia, Treatment, Drug, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011311
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Chemotherapy Induced Anemia Market grew from USD 2.51 billion in 2023 to USD 2.70 billion in 2024. It is expected to continue growing at a CAGR of 7.36%, reaching USD 4.14 billion by 2030.

Chemotherapy Induced Anemia (CIA) is a prevalent condition in cancer patients undergoing chemotherapy, characterized by a hemoglobin deficiency due to the cytotoxic effects of the treatment on bone marrow. The necessity of addressing CIA stems from its significant impact on patient quality of life and treatment outcomes, necessitating effective management and therapeutic interventions to alleviate symptoms and improve patient adherence to cancer treatment regimens. CIA management finds application in hematology and oncology clinics and hospitals, driving the need for supportive care therapies, including erythropoiesis-stimulating agents, blood transfusions, and iron supplements. The end-use scope prominently involves healthcare providers, cancer centers, and patients. Market insights reveal robust growth influenced by increasing cancer prevalence, advancements in chemotherapy treatments, and heightened emphasis on supportive care strategies. Key growth factors include the rise in awareness about anemia treatment options, innovation in biologic drugs, and supportive regulatory policies enhancing product approvals. However, opportunities lie in extensive research and development aimed at discovering novel iron preparations and non-invasive therapies, tapping into emerging markets where cancer incidence is rising. Potential challenges affecting market growth include high costs of treatment, stringent regulatory landscapes, adverse effects associated with current therapies, and limitations in addressing complex patient needs such as those with comorbidities. Innovative research areas for business growth involve developing safer, more effective ESA formulations, exploring gene therapy, and utilizing artificial intelligence for personalized treatment approaches. The nature of the CIA market is dynamic, characterized by fast-paced advancements and competitive pressures among key players. Companies should focus on strategic collaborations with research institutions, enhancing patient education programs, and leveraging digital health technologies to expand their reach and streamline monitoring and treatment processes. Addressing these facets can position stakeholders to capitalize on burgeoning opportunities and mitigate existing market challenges.

Understanding Market Dynamics in the Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of cancer and anemia among geriatric patients
    • Rising availability of number of chemotherapy agents
    • Favorable governmental initiatives in development of chemotherapy-induced anemia drugs
  • Market Restraints
    • Certain risks associated with anemia during chemotherapy
  • Market Opportunities
    • Innovations in the field of chemotherapy-induced anemia
    • Increasing collaborations and investments to enhance the research and development for anemia drug developments
  • Market Challenges
    • Lower efficacy of the chemotherapy-induced thrombocytopenia treating drugs

Exploring Porter’s Five Forces for the Chemotherapy Induced Anemia Market

Porter’s Five Forces framework further strengthens the insights of the Chemotherapy Induced Anemia Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chemotherapy Induced Anemia Market

External macro-environmental factors deeply influence the performance of the Chemotherapy Induced Anemia Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Anemia Market, highlighting leading vendors and their innovative profiles. These include 3SBIO Inc., Amgen Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., PhytoHealth Corporation, SBI Pharmaceuticals, and Therapure Biopharma Inc..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Anemia Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Range Of Anemia
    • Life-Threatening Anemia
    • Mild Anemia
    • Moderate Anemia
    • Severe Anemia
  • Treatment
    • Erythropoiesis-Stimulating Agents
    • Iron Supplementation
    • RBC Transfusions
  • Drug
    • Androxy Oral
    • Aranesp Injection
    • Epoetin Alfa Injection
    • Epogen Injection
    • Procrit Injection
  • End-User
    • Ambulatory Surgical Centers
    • Cancer Rehabilitation Centers
    • Cancer Research Centers
    • Hospitals
    • Multispecialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer and anemia among geriatric patients
5.1.1.2. Rising availability of number of chemotherapy agents
5.1.1.3. Favorable governmental initiatives in development of chemotherapy-induced anemia drugs
5.1.2. Restraints
5.1.2.1. Certain risks associated with anemia during chemotherapy
5.1.3. Opportunities
5.1.3.1. Innovations in the field of chemotherapy-induced anemia
5.1.3.2. Increasing collaborations and investments to enhance the research and development for anemia drug developments
5.1.4. Challenges
5.1.4.1. Lower efficacy of the chemotherapy-induced thrombocytopenia treating drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Chemotherapy Induced Anemia Market, by Range Of Anemia
6.1. Introduction
6.2. Life-Threatening Anemia
6.3. Mild Anemia
6.4. Moderate Anemia
6.5. Severe Anemia
7. Chemotherapy Induced Anemia Market, by Treatment
7.1. Introduction
7.2. Erythropoiesis-Stimulating Agents
7.3. Iron Supplementation
7.4. RBC Transfusions
8. Chemotherapy Induced Anemia Market, by Drug
8.1. Introduction
8.2. Androxy Oral
8.3. Aranesp Injection
8.4. Epoetin Alfa Injection
8.5. Epogen Injection
8.6. Procrit Injection
9. Chemotherapy Induced Anemia Market, by End-User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Cancer Rehabilitation Centers
9.4. Cancer Research Centers
9.5. Hospitals
9.6. Multispecialty Clinics
10. Americas Chemotherapy Induced Anemia Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chemotherapy Induced Anemia Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chemotherapy Induced Anemia Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CHEMOTHERAPY INDUCED ANEMIA MARKET RESEARCH PROCESS
FIGURE 2. CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CHEMOTHERAPY INDUCED ANEMIA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CHEMOTHERAPY INDUCED ANEMIA MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CHEMOTHERAPY INDUCED ANEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHEMOTHERAPY INDUCED ANEMIA MARKET DYNAMICS
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY LIFE-THREATENING ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MILD ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MODERATE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY SEVERE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY IRON SUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RBC TRANSFUSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ANDROXY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ARANESP INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY EPOETIN ALFA INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY EPOGEN INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY PROCRIT INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY CANCER REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 42. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 44. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 46. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 48. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 64. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 66. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 68. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 70. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 72. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 76. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 78. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 80. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 84. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 88. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 92. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 96. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 100. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 102. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 104. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 113. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 115. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 117. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 118. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 119. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 121. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 123. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 125. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 127. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 133. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 137. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 139. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 145. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 149. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 150. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 151. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 153. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 154. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 155. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 157. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 159. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 175. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 181. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 185. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 187. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. CHEMOTHERAPY INDUCED ANEMIA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 197. CHEMOTHERAPY INDUCED ANEMIA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Chemotherapy Induced Anemia market, which are profiled in this report, include:
  • 3SBIO Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • SBI Pharmaceuticals
  • Therapure Biopharma Inc.

Methodology

Loading
LOADING...

Table Information